111 related articles for article (PubMed ID: 31455117)
1. Advances in the therapy of BRAF
Jin Z; Sinicrope FA
Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
[No Abstract] [Full Text] [Related]
2. Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer.
Ozeki H; Shimada Y; Nakano M; Kondo S; Ohashi R; Miwa Y; Yamai D; Matsumoto A; Abe K; Tajima Y; Ichikawa H; Sakata J; Takii Y; Sugai M; Nagai T; Ling Y; Okuda S; Wakai T
Hum Pathol; 2024 Mar; 145():71-79. PubMed ID: 38423222
[TBL] [Abstract][Full Text] [Related]
3. The effect of BRAF
Liposits G; Winther SB; Ryg J; Skuladottir H; Möller S; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
J Geriatr Oncol; 2024 Mar; 15(2):101632. PubMed ID: 37730481
[No Abstract] [Full Text] [Related]
4. Management of
Takeda H; Sunakawa Y
Front Oncol; 2021; 11():602194. PubMed ID: 33842313
[No Abstract] [Full Text] [Related]
5. BRAF
Planchard D; Sanborn RE; Negrao MV; Vaishnavi A; Smit EF
NPJ Precis Oncol; 2024 Apr; 8(1):90. PubMed ID: 38627602
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Piercey O; Tie J; Hollande F; Wong HL; Mariadason J; Desai J
Clin Colorectal Cancer; 2024 Apr; ():. PubMed ID: 38816264
[TBL] [Abstract][Full Text] [Related]
7. Molecular Testing for Gastrointestinal Cancer.
Lee HS; Kim WH; Kwak Y; Koh J; Bae JM; Kim KM; Chang MS; Han HS; Kim JM; Kim HW; Chang HK; Choi YH; Park JY; Gu MJ; Lhee MJ; Kim JY; Kim HS; Cho MY; ;
J Pathol Transl Med; 2017 Mar; 51(2):103-121. PubMed ID: 28219002
[TBL] [Abstract][Full Text] [Related]
8. Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.
Miyamoto Y; Zhang W; Lenz HJ
Indian J Surg Oncol; 2017 Dec; 8(4):580-590. PubMed ID: 29203992
[TBL] [Abstract][Full Text] [Related]
9. Colorectal medullary carcinoma: a pathological subtype with intense immune response and potential to benefit from immune checkpoint inhibitors.
Zou H; Liu C; Ruan Y; Fang L; Wu T; Han S; Dang T; Meng H; Zhang Y
Expert Rev Clin Immunol; 2024 Mar; ():1-12. PubMed ID: 38459764
[TBL] [Abstract][Full Text] [Related]
10. Recent insights into nanotechnology development for detection and treatment of colorectal cancer.
Viswanath B; Kim S; Lee K
Int J Nanomedicine; 2016; 11():2491-504. PubMed ID: 27330292
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
Herr R; Brummer T
Mol Cell Oncol; 2015; 2(4):e1002709. PubMed ID: 27308494
[TBL] [Abstract][Full Text] [Related]
12. Updates on the Management of Colorectal Cancer in Older Adults.
O'Donnell CDJ; Hubbard J; Jin Z
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791899
[TBL] [Abstract][Full Text] [Related]
13. [Contributions of molecular biology to the management of colorectal cancer].
Grancher A; Cuissy S; Sefrioui D; Di Fiore F
Rev Prat; 2024 Apr; 74(4):355-358. PubMed ID: 38814021
[TBL] [Abstract][Full Text] [Related]
14. Improvements in Clinical Outcomes for
Morris VK; Bekaii-Saab T
Clin Cancer Res; 2020 Sep; 26(17):4435-4441. PubMed ID: 32253230
[TBL] [Abstract][Full Text] [Related]
15. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
16. Targeting BRAF mutations in non-small cell lung cancer.
O'Leary CG; Andelkovic V; Ladwa R; Pavlakis N; Zhou C; Hirsch F; Richard D; O'Byrne K
Transl Lung Cancer Res; 2019 Dec; 8(6):1119-1124. PubMed ID: 32010589
[TBL] [Abstract][Full Text] [Related]
17. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.
Caputo F; Santini C; Bardasi C; Cerma K; Casadei-Gardini A; Spallanzani A; Andrikou K; Cascinu S; Gelsomino F
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661924
[TBL] [Abstract][Full Text] [Related]
18. Management of V600E and V600K BRAF-Mutant Melanoma.
Haugh AM; Johnson DB
Curr Treat Options Oncol; 2019 Nov; 20(11):81. PubMed ID: 31741065
[TBL] [Abstract][Full Text] [Related]
19. [BRAF V600E-mutant colorectal cancers: Where are we?].
Lièvre A; de la Fouchardière C; Samalin E; Benoist S; Phelip JM; André T; Lledo G
Bull Cancer; 2020 Sep; 107(9):881-895. PubMed ID: 32674932
[TBL] [Abstract][Full Text] [Related]
20. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.
Afrăsânie VA; Marinca MV; Alexa-Stratulat T; Gafton B; Păduraru M; Adavidoaiei AM; Miron L; Rusu C
Radiol Oncol; 2019 Sep; 53(3):265-274. PubMed ID: 31553708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
